Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study

Maria Ekelund1,2, Kristiina Aalto3, Anders Fasth4, Troels Herlin5, Susan Nielsen6, Ellen Nordal7,8, Suvi Peltoniemi3, Marite Rygg9,10, Marek Zak6, Lillemor Berntson2* and on behalf of the Nordic Study Group of Pediatric Rheumatology (NoSPeR)

Abstract

Background: To study the impact of psoriasis and features associated with psoriasis on classification and outcome in a population-based follow-up cohort of children with juvenile idiopathic arthritis (JIA).

Methods: In all, 440 children with JIA were followed for a median of 8 years in a prospective Nordic population-based cohort study. Data for remission was available for 427 of these children. The presence of psoriasis, psoriasis-like rash, dactylitis, nail pitting, enthesitis, tenosynovitis and heredity was assessed in relation to ILAR classification and remission.

Results: Clinical findings associated with psoriasis developed consecutively during the 8-year period. Six of 14 children with psoriasis were not classified as juvenile psoriatic arthritis according to the ILAR criteria at 8 year follow-up. Dactylitis was more common in children with early onset of JIA. After 8 years we found a cumulative median number of eleven arthritic joints in children with psoriasis or psoriasis-like rash compared with six in the rest of the cohort (p = 0.02). Also, the chance for not being in remission after 8 years increased significantly in patients with psoriasis, psoriasis-like rash or at least two of: 1) first-degree heredity for psoriasis or psoriatic arthritis, 2) dactylitis or 3) nail pitting, compared with the rest of the group (OR 3.32, p = 0.010).

Conclusions: Our results indicate a more severe disease over time in psoriasis-associated JIA, as features of psoriasis develop during the disease course. This group is a major challenge to encompass in a future JIA classification in order to facilitate early tailored treatment.

Keywords: Arthritis, Juvenile Rheumatoid, Psoriasis, Child

Background

Classification of children with JIA and features of psoriasis has challenged the research community for decades. The disease comprises a variety of features often developing over the years, with large heterogeneity. Since classification criteria have varied over time there have also been dissimilarities in the cohorts studied. The question has been raised whether juvenile psoriatic arthritis (JPsA) is an entity of its own [1] or whether psoriasis and juvenile arthritis develop only as separate entities [2–4]. Adult psoriatic arthritis (PsA) is considered a unique disease entity, clearly distinct from rheumatoid arthritis. Immunology research has revealed that molecules of the interleukin-23 and interleukin-17 pathways promote skin and joint inflammation in psoriasis [5]. These discoveries have led to efforts to target interleukin-23, interleukin-17 and related molecules to treat psoriasis and psoriatic arthritis [6].

Classification of JPsA has been a challenge. In 1989, the Vancouver criteria for JPsA were presented comprising...
two categories of JPsA, one definite and one probable [7]. In three studies utilizing the Vancouver classification criteria, joint patterns differed at onset between oligoarticular JIA and oligoarticular JPsA, with greater involvement of small joints in the hands and wrists being more typical in the latter category [1, 8, 9]. Age at onset was significantly higher in oligoarticular JPsA compared with oligoarticular JIA. A child with an oligoarticular pattern with wrists or small joints in hands or feet affected, more often had nail pitting, psoriasis or heredity for psoriasis.

In the current ILAR classification, JPsA may be diagnosed in children with arthritis and (1) psoriasis or (2) if two features suggestive of a psoriatic diathesis are present, including dactylitis, nail changes, or psoriasis in a first-degree relative, in the absence of specific exclusions [10].

During later years two distinct phenotypic subgroups of JPsA have been discussed. One occurs in children (predominantly girls) younger than 5 years of age at onset, with small joint involvement, a higher risk of progression to polyarticular disease, high frequency of ANA positivity and dactylitis. In contrast, children above 5 years of age at onset had no obvious gender difference, were more likely to be ANA negative and to exhibit enthesis and axial joint involvement [7, 11, 12].

So far, the prognosis for JPsA has been considered approximately the same as for patients with other categories of JIA based on two follow-up studies, one using both the Vancouver and the ILAR criteria with a follow-up time of 1 month, up to 16.8 years [2] and the second using the Vancouver criteria with a median follow-up time of 2 years [13]. Children with a polyarticular course had the worst prognosis. Positive ANA in children with JPsA has been discussed as a negative prognostic factor without any conclusive results [7, 9, 14]. Occurrence of HLA-B27 has been shown as a risk factor for sacroiliitis in JPsA [2].

In light of this knowledge, we wanted to challenge earlier findings by studying a well-defined cohort of children with JIA, followed prospectively over a long time, especially since previous studies were referral-based. Our aim was to study the occurrence of variables indicating psoriatic diathesis during the first 8 years of disease in a population-based cohort of children with JIA and to address aspects of classification and outcome.

**Methods**

Patients were recruited from a Nordic JIA cohort. All new patients with JIA from defined geographical areas of Denmark, Finland, Norway, and Sweden were collected prospectively during 1997–2000 [15]. The study design was population-based. All physicians within each catchment area eligible to meet children with arthritis received a letter informing about the study. Pediatric rheumatologists from 12 participating centers included patients. The database consisted of clinical and laboratory data from 500 patients, including 440 followed for at least 7 years, median 98 months. The 60 patients lost to follow-up did not differ from the 440 with follow-up data as regards number of active joints during the first 6 months after onset, Childhood Health Assessment Questionnaire (CHAQ), Juvenile Arthritis Disease Activity Score (JADAS27), or proportion with oligoarticular disease at baseline. Also, occurrence of psoriasis, psoriatic-like rash, dactylitis, enthesis, first degree heredity for psoriasis or psoriatic arthritis did not differ between the 60 lost to follow-up compared to the 440 in the study cohort. JIA categories had been determined based on the ILAR criteria [10]. For 427 of 440 children, outcome data was available for analysis of remission. The presence of psoriasis and psoriasis-like rash during the 8-year follow-up period was assessed in relation to clinical characteristics, ILAR classification and remission. Remission status according to the preliminary criteria of Wallace et al was used [16]. Clinical variables were collected cumulatively during this period; they were not necessarily present at the time of the 8-year follow-up. A patient was considered to have psoriasis if a dermatologist had made that diagnosis. Rashes noted by the examining rheumatologist, well skilled in pediatric rheumatology, and thought likely (but not definitely) to represent psoriasis were considered psoriasis-like.

**Results**

In the cohort of 440 children followed for at least 7 years after disease onset (median 98 months, range 84–147 months), 14 children developed psoriasis and 13 psoriasis-like rash (Table 1). Only 8 of the 14 children with psoriasis and JIA were classified as juvenile psoriatic arthritis (JPsA) according to the ILAR criteria. The other six were classified as undifferentiated. Four of those were mutually excluded from JPsA as well as enthesitis related arthritis (ERA), thus they did not fit any category. One boy was excluded because he was older than six at onset and HLA-B27 positive, and another child was excluded because of positive rheumatoid factor (RF). Children with dactylitis and/or nail pitting were found among many ILAR categories. First-degree heredity for psoriasis or psoriatic arthritis occurred in 9 of 14 children with JPsA and in 51 of 57 of children classified as undifferentiated arthritis. In a comparison between the eight children with psoriasis, classified as JPsA (ILAR criteria) at 98 months of disease, and the six children with psoriasis classified as undifferentiated, there was no significant difference in age at onset ($p = 0.34$), first degree heredity for psoriasis/psoriatic arthritis ($p = 0.53$), dactylitis ($p = 1.0$), nail pitting ($p = 0.30$) or cumulative number of joints ($p = 0.59$), but the cohorts were too
small for meaningful statistical analyses. Children with psoriasis \((n = 14)\) compared to those with psoriatic-like rash \((n = 13)\) did not differ regarding gender \((p = 0.71)\), outcome \((p = 0.16)\) or median cumulative number of joints \((p = 0.26)\).

Table 2 presents the development of clinical features associated with psoriasis during the first 8 years of disease. Twenty-four children developed dactylitis during disease course, 15 of them had dactylitis at onset. Median age at time of onset of JIA in the group with dactylitis was 2.4 (IQR 1.7–5.4) years compared with 5.8 (IQR 2.7–9.9) years in the rest of the cohort \((p = 0.007)\). Five of 24 children with dactylitis developed psoriasis or psoriatic-like rash during the first 8 years of their arthritis, Table 3. Table 3 also presents the significantly higher cumulative number of active joints in children with psoriasis or psoriatic-like rash as well as the increased frequency of dactylitis, nail pitting, enthesitis, and first-degree heredity for psoriasis compared with children without psoriasis or psoriatic-like rash.

Features of sacroiliitis (SI) developed in several children with psoriasis or psoriatic-like rash (Table 4). SI or enthesitis coexisting with psoriasis or psoriatic-like rash lead to mutual exclusion from both JPsA and ERA categories.

Seven of 27 children with psoriasis or psoriatic-like rash were HLA-B27 positive (missing value in another three) and this group had a high age of onset (median 10.8, IQR 5.9–11.8 years), and a high cumulative number of joints (median 15, IQR 9–18 joints), data not shown. Several of the ERA or SI-like features were clustered together. Six of the 27 children with psoriasis or psoriatic-like rash had inflammatory back pain or buttock pain at any time during the first 98 months of disease (Table 4), three of those were HLA-B27 positive, and in two sacroiliitis was confirmed by x-ray.

In children with psoriasis or psoriatic-like rash or at least two of either dactylitis, nail pitting, or first-degree heredity for psoriasis, the remission rate was significantly lower compared with children without these clinical features, \(p = 0.010\) (Table 5). First-degree heredity for psoriasis in children with oligoarticular onset did not increase the risk for oligoarticular extended disease during those first 8 years of disease (data not shown).

Statistical analysis

Statistical analyses were performed using the Statistical Package for Social Sciences, version 23 (SPSS Inc., Chicago, IL, USA). Demographics and disease characteristics were described using median and interquartile range (IQR), or total number and percent of study cohort. Statistical analyses of differences between children with and without psoriasis/psoriatic-like rash during the first year of disease were performed using the chi-square test (Fisher’s exact test, 2-sided) for comparison of dichotomous variables. The Mann-Whitney \(U\)-test was used for comparison of non-parametric data and independent samples was used for comparison of median values between the two groups.
Binary logistic regression analyses were performed in order to identify the association between occurrence of psoriasis or psoriasis-like rash and failure of remission 8 years after disease onset. The dichotomized variable remission (remission without medication) versus remission with medication or not in remission was used as the dependent variable in the regression model. Results of the regression analyses are shown as odds ratios (OR), 95% confidence intervals (CI) and \( p \)-values. The level of significance was set at 5% (\( p < 0.05 \)).

**Discussion**

In this population-based study of 440 patients followed for a median of 98 months, we found that as many as six of 14 children with definite psoriasis were classified as undifferentiated JIA based on exclusion criteria in the ILAR classification. In children with psoriasis or psoriasis-like rash we found a strong association with first-degree heredity for psoriasis or psoriatic arthritis, dactylitis and nail pitting, but also with enthesitis. Psoriasis or psoriasis-like rash was also associated with higher cumulative number of active joints and possibly with less favorable outcome, as features of psoriasis are additive.

A strength of our study was the prospective population-based design and also that the whole cohort was followed for at least 7 years. A weakness was that the group of children with psoriasis or psoriasis-like rash was small and no dermatologist verified the psoriasis-like rash. The pediatric rheumatologists involved in the study all had several years’ experience and a psoriasis-like rash was only defined if there was a high suspicion of psoriasis.

Another clinical sign, dactylitis, has proven a strong predictor of JPsA [13]. In preparatory studies for classification of psoriatic arthritis in adults (CASPAR criteria), the specificity of dactylitis was shown to be 95%, nail dystrophy 98% and tender enthesitis and diffuse enthesitis pain 77–93% [17]. The strong association between psoriatic arthritis, dactylitis, nail changes and enthesitis is in accord with our results. In our study cohort occurrence of dactylitis was spread among ILAR categories, but had a strong association with psoriasis or psoriasis-like rash. Also, enthesitis showed a strong association with psoriasis or psoriasis-like rash in our study cohort. Although enthesitis is a well-recognized feature of PsA in adults, it is an exclusion criterion for JPsA in the ILAR classification, and a common reason for exclusion from the JPsA category [15]. Another important feature in psoriatic diathesis in adults is heredity for psoriasis [17] and our results pointed in the same direction.

In our cohort, first-degree heredity for psoriasis was common in the undifferentiated JIA category, which has

### Table 3
Clinical features describing the first eight years of disease in 440 children with JIA according to occurrence of psoriasis or psoriasis-like rash

| Clinical feature                             | Number of patients assessed | Total cohort   | Psoriasis or psoriasis-like rash \( n = 27 \) | No psoriasis or psoriasis-like rash \( n = 413 \) | \( p \)-value |
|---------------------------------------------|-----------------------------|----------------|---------------------------------------------|---------------------------------------------|--------------|
| Gender, n (% females)                       | 440 (66.1)                  | 440 (66.1)     | 27 (48.1)                                  | 413 (67.3)                                  | 0.06         |
| Age at time of onset median (IQR)           | 440                          | 4.5 (2.5-9.7)  | 7.2 (3.8-11.0)                             | 5.3 (2.3-9.4)                               | 0.08         |
| Cumulative joints median (IQR)              | 440                          | 6 (2-12)       | 11 (5-16)                                  | 6 (2-12)                                   | 0.02         |
| Dactylitis (%)                              | 440                          | 24             | 5 (18.5)                                   | 19 (4.6)                                   | 0.01         |
| Nail pitting (%)                            | 440                          | 18             | 7 (25.9)                                   | 11 (2.7)                                   | <0.001       |
| First-degree heredity for psoriasis or psoriatic arthritis (%) | 420                  | 51             | 7 (25.9)                                   | 44 (10.6)                                  | 0.03         |
| Enthesitis (%)                              | 438                          | 41             | 6 (22.2)                                   | 35 (8.5)                                   | 0.03         |
| Tenosynovitis (%)                           | 436                          | 88             | 6 (22.2)                                   | 82 (19.8)                                  | 0.81         |

\*Patients with psoriasis or psoriasis-like rash compared with those without, \( \text{aFisher’s exact test, } \text{bIndependent samples Mann-Whitney } U \text{ test, } \text{cIndependent samples median test} \)

### Table 4
Development of clinical variables during a follow-up time of at least seven years after onset (median 98, range 84–147 months) in groups of patients included in a cohort of 440 Nordic patients with JIA

| Psoriasis or psoriasis-like rash \( n = 27 \) | Dactylitis \( n = 24 \) |
|---------------------------------------------|-------------------------|
| Radiological SI\( ^p \)                     |                         |
| At onset                                    | 0                       |
| Cumulative at median 98 months              | 2                       |
| Inflammatory back pain/buttock pain         |                         |
| At onset                                    | 3                       |
| Cumulative at median 98 months              | 6                       |
| Enthesitis                                  |                         |
| At onset                                    | 5                       |
| Cumulative at median 98 months              | 6                       |

\( ^p \text{Number of patients with the feature developing during the first median 98 months} \)

\( ^p \text{SI sacroiliitis} \)
also been discussed by others and illustrates the classification difficulties [18]. Stoll et al studied classification of juvenile psoriatic arthritis and found that the ILAR criteria excluded almost 60% of those included with the Vancouver criteria [19], which is in line with our results regarding ILAR classification.

Another challenge in classification is the progression of the disease over time. In an earlier publication we showed that patients classified as JPsA according to the ILAR criteria increased from 6 to 14 during the follow-up period. In about half of the children with JPsA, the classic rash presented after the onset of arthritis, with a time lag that could be 10 years or more [20]. Manifestations of psoriasis in the young child are often atypical or unspecific, such as erythema and scaling behind the ears, features taken into consideration by the Vancouver set of JPsA criteria, but excluded under the JIA nomenclature in the ILAR classification [7]. Our data presents the heterogeneity of JPsA and the development over time of clinical variables supporting a psoriatic diathesis, as well as the overlap between JPsA and enthesitis-related arthritis in a group of patients.

The earlier findings of two phenotypic subgroups of JPsA: a younger group, predominantly girls, with a polyarticular onset, high frequency of ANA positivity and dactylitis [13], in contrast to an older age group more likely to exhibit enthesitis and axial joint involvement [7, 13], can only partly be confirmed by our results since our cohort was too small for further analysis. We found a significantly lower age at time of onset in children who developed dactylitis during the 8 years, compared with those who did not. None of the 15 children with dactylitis at disease onset developed inflammatory back pain during the disease course and in the extended group of 24 children with dactylitis after 8 years, none developed any sign of sacroiliitis. This result is consistent with a previous observation that patients with dactylitis and sacroiliitis tend to be distinctive phenotypic groups of juvenile psoriatic arthritis [21]. Our finding of an older age at onset in the group of HLA-B27 positive children with psoriasis or psoriasis-like rash also supports earlier data, but we were surprised by the very high cumulative number of joints with arthritis in this group. The polyarticular disease progression in children with psoriasis and arthritis in our study is in line with earlier studies [7, 9, 12]. Our result indicates a somewhat less favorable outcome in the cohort of children with psoriasis, psoriasis-like rash or at least two well-known features characterizing the JPsA group, but our numbers are too low to analyze each of the clinical features as a single trait, and larger studies are needed to confirm our results. The prognosis in JPsA defined according to the Vancouver classification criteria was not worse compared with other JIA categories in earlier studies [2, 13], but the time of follow-up varied: 1 month in one study up to 17 years, and a median of 23 months in the other. By comparison, our cohort was followed for at least 7 years, with a median of 98 months, and in a population-based setting.

Since classification of JPsA has changed over time, it is difficult to compare one study with another and to properly present outcomes in this group of patients. In our study clinical findings associated with psoriasis as

Table 5 Analyses of binary logistic regression for not being in remission related to psoriasis and psoriasis-related variables in 427 children with JIA, followed for at least seven years of disease

| Number of patients | Not in remission after 8 years n (%) | p-value | OR | 95% confidence interval |
|--------------------|-------------------------------------|---------|----|------------------------|
| Psoriasis or psoriasis-like rash* | Yes 25 | 19 (76.0) | 0.062 | 2.44 | 0.96-6.2 |
| No 402 | 227 (56.5) | | | |
| Psoriasis or psoriasis-like rash OR at least two of threeb | Yes 31 | 25 (80.6) | 0.010 | 3.32 | 1.33-8.27 |
| No 379 | 211 (55.7) | | | |
| Dactylitis | Yes 24 | 16 (66.7) | 0.36 | 1.5 | 0.63-3.6 |
| No 403 | 230 (57.1) | | | |
| Nail pitting | Yes 18 | 13 (72.2) | 0.21 | 1.96 | 0.69-5.6 |
| No 409 | 233 (57.0) | | | |
| Enthesitis | Yes 40 | 29 (72.5) | 0.046 | 2.08 | 1.01-4.29 |
| No 385 | 215 (55.8) | | | |
| First-degree heredity for psoriasis or psoriatic arthritis | Yes 48 | 28 (58.3) | 0.86 | 1.1 | 0.42-2.82 |
| No 361 | 208 (57.6) | | | |
| Total | 427 | 181 (42.4) | | | |

*aData in 13 patients with psoriasis and 12 with psoriasis-like rash
b1) dactylitis, 2) nail pitting, 3) first-degree heredity for psoriasis or psoriatic arthritis

Remission was defined as inactive disease off medication for at least twelve months in accordance with the preliminary definition of Wallace [16]
well as first-degree heredity for psoriasis were strongly associated with children developing psoriasis or psoriasis-like rash during the first 8 years of disease. Our cohort also reveals the difficulty of using the ILAR classification to assign those children. The consequence is that we do not study children with a psoriatic diathesis specifically, which would be important in relation to new therapies under development for JPsA and bringing these children new treatment possibilities.

Conclusions

We suggest stronger emphasis on the variables of psoriatic diathesis, and not using strict exclusion criteria in future follow-up studies of JIA, and to consider this also in future JIA classifications. We need to better understand how to predict this category of disease and to be able to tailor proper treatment for this group of children.

Abbreviations

CHAQ: Childhood health assessment questionnaire; CI: Confidence interval; ERA: Enthesitis related arthritis; ILAR: The international league of associations for rheumatology; IQR: Interquartile range; JADAS27: Juvenile arthritis disease activity score; JIA: Juvenile idiopathic arthritis; JPsA: Juvenile psoriatic arthritis; PsA: Psoriatic arthritis; RF: Rheumatoid factor

Acknowledgements

We thank the children and parents participating in the study. We also thank the participating nurses as well as the other members of the Nordic Study Group of Pediatric Rheumatology (NCGPfR), Gudmund Marhaug (Trondheim), Freddy Karup Pedersen (Copenhagen), Pirrikko Pellkonen (Helsinki), and Boel Anderson-Gäre (Jönköping), for their inspiring cooperation. Finally, we thank the following participating physicians who contributed by collecting data: Nils Thomas Songstad (Trondheim), Kjetil Berntzen and Nina Moe (Trondheim), Mikael Dammgaard, Maria Ekelund, and Nils Olof Jonsson (Jönköping), Anders Berner and Hans Ekstrom (Karlstad), Eric Ronge (Skövde), Agne Lind and Lars Hammaren (Borås), Johan Robinsson (Trollhättan), and Anna-Lena Nilsson (Östersund).

Funding

This work was supported by grants from the Department of Women’s and Children’s Health, Uppsala University Hospital, Uppsala, the Gillbergska foundation, Uppsala, the Futurum – academy of health and care, Region Jönköping county and the Swedish Rheumatism association.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available for ethical reasons, as well as privacy reasons, but are available from the Nordic Study group on reasonable request.

Authors’ contributions

All authors were involved in planning and performance of the study, inclusion of patients and data collection. ME and LB conceptualized and drafted the manuscript. All authors have reviewed and edited the manuscript, as well as read and approved the final version.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The Research Ethical Committees in each respective country gave their approval in accordance with national practices and legislation, in Sweden Uppsala ethical board, Dnr 2004, M-357. Oral informed consent was required and written informed consent was obtained from children ≥ 15 years of age and from parents/legal guardians of children aged < 15 years, but with some variation between countries.

Author details

1Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden.
2Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden.
3Department of Pediatrics, Children’s Hospital, Helsinki University Hospital, Helsinki, Finland.
4Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
5Department of Pediatrics, Århus University Hospital, Århus, Denmark.
6Pediatric Rheumatology Department, Pediatric Clinic B, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
7Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway.
8Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
9Department of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway.
10Department of Pediatrics, St. Olav’s Hospital, Trondheim, Norway.

Received: 25 November 2016 Accepted: 16 February 2017

Published online: 22 February 2017

References

1. Stoll ML, Nigrovic PA, Gotte AC, Punaro M. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29(8):S58–8.
2. Butbul Aviel Y, Tyrrell P, Schneider R, Dhillion S, Feldman LM, Laxer R, et al. Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis? Pediatr Rheumatol Online J. 2013;11:11.
3. Petty RE. Juvenile psoriatic arthritis, or juvenile arthritis with psoriasis? Clin Exp Rheumatol. 1994;12 Suppl 10:S55–8.
4. Ravelli A, Consolato A, Schiappapietra B, Martini A. The conundrum of juvenile psoriatic arthritis. Clin Exp Rheumatol. 2015;33:540–3.
5. Gaffen SL, Jain R, Garg AV, Cui DJ. The L-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585–600.
6. Ritchlin CT, Krueger JG. New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016;28:204–10.
7. Southwood TR, Petty RE, Malleson PN, Delgado EA, Hunt DW, Wood B, et al. Psoriatic arthritis in children. Arthritis Rheum. 1989;32:1007–13.
8. Huemer C, Malleson PN, Cabral DA, Huemer M, Falger J, Zidek T, et al. Patterns of joint involvement at onset differentiates oligoarticular juvenile psoriatic arthritis from pauciarticular juvenile rheumatoid arthritis. J Rheumatol. 2002;29:1531–5.
9. Robertson DM, Cabral DA, Malleson PN, Petty RE. Juvenile psoriatic arthritis: follow-up and evaluation of diagnostic criteria. J Rheumatol. 1996;23:166–70.
10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:590–2.
11. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23:437–43.
12. Lambert J. Psoriatic arthritis in Childhood. Clin Rheum Dis. 1976;2:339–52.
13. Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54:3564–72.
14. Shore A, Ansell BM. Juvenile psoriatic arthritis—an analysis of 60 cases. J Pediatr. 1982;100:529–35.
15. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:2809–18.
16. Wallace CA, Cupertino N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290–4.
17. Taylor W, Gladman D, Hellisell P, Marchesoni A, Mease P, Melants H, et al. Classification criteria for psoriatic arthritis development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.
18. Chan MO, Petty RE, Guzman J, ReACCh-Out Investigators. A Family History of Psoriasis in a First-degree Relative in Children with JIA: to Include or Exclude? J Rheumatol. 2016;43(5):944–7.
19. Stoll ML, Lio P, Sundel RP, Nigrovic PA. Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum. 2008;59:51–8.
20. Farber EM, Carlson RA. Psoriasis in childhood. Calif Med. 1966;105:415–20.
21. Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol. 2010;37:2402–8.